期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 9, 期 5, 页码 663-670出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.09.14
关键词
essential thrombocythemia; JAK2 inhibitor; myelofibrosis; myeloproliferative neoplasm; polycythemia vera
类别
资金
- Cephalon
- Incyte
- Exelixis
- SBio
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biology of those disorders. Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: almost all patients with polycythemia vera harbor the mutation and about 50% of patients with essential thrombocythemia and primary myelofibrosis have the mutation, making the development of JAK2 tyrosine kinase inhibitors an attractive therapeutic goal. In addition, inhibition of JAK2 kinase may have a therapeutic role in other hematologic malignancies, such as chronic myeloid leukemia or lymphoma. A number of molecules that inhibit JAK2 kinase have been described in the literature, and several are being evaluated in a clinical setting. Here, we summarize current clinical experience with JAK2 inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据